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Research and Development of Drugs 
for Developing Countries Faces Many 
Barriers
What you need to know:
R&D for neglected diseases faces a number of 
barriers. In order to expand R&D, all of the actors 
– governments, companies, and NGOs, among 
others – need to work together on solutions. The 
limitations of the prize fund model and PPPs need 
to be addressed.
What is this research about?
Research and development (R&D) of new medicines 
is driven by the market – for the most part, large 
numbers of people with chronic diseases who live in 
first world countries. Drug companies are willing to 
invest in R&D because they can make a substantial 
profit from this pool of potential patients. The 
market-driven model for R&D, however, has failed 
when it comes to dealing with neglected diseases 
in developing countries (Type III diseases). Drug 
companies devote very little of their resources to 
creating medicines for these diseases. And when 
drugs are created, they tend to be of low value 
because they don’t address the specific conditions in 
these countries. A drug may need to be administered 
in a hospital setting to which people don’t have 
access. Or it may simply be unaffordable. 
The problem is not just that companies aren’t 
focusing on neglected diseases. Developing countries 
also share many diseases with first world countries. 
Type I diseases, like diabetes, afflict large numbers of 
vulnerable people in both developing and developed 
countries, while Type II diseases tend to afflict a 
greater proportion of people in developing countries. 
But there is little market incentive to invest in 
medicines that are tailored to the specific resources, 
conditions, and needs of people in the developing 
world.
What did the researcher do?
Joel Lexchin, a Professor at York University, looked 
at the systematic barriers that impede research into 
diseases that afflict developing countries. He also 
considered the strengths and weaknesses of three 
specific proposals aimed at increasing R&D for these 
diseases. 
What did the researcher find?
There are five barriers to expanding research 
capacity for health problems facing the developing 
world: Priority Setting; Coordination of Research 
Efforts; Intellectual Property Rights and Publicly 
Funded Research; Intellectual Property Rights and 
Patent Thickets; and Clinical Trial Capacity. Donors 
who give money to fight particular diseases often set 
the priorities for research. But donor funding does 
not always address the actual needs of particular 
countries. Health care workers, on the ground in 
developing countries, need to be involved. So, too, 
do the people who will be on the receiving end of 
any new research initiatives. In general, research 
efforts in and between donor countries often lack 
coordination. Governments do not necessarily know 
where they are allocating their research dollars. This 
can result in redundant work, gaps in policy, and a 
general lack of coherence. Universities often have 
exclusive rights to drugs they develop with public 
money. As a result, they tend to restrict access to 
the results of their research in the hopes of making 
money through licensing their patents to large drug 
companies. The rapid increase in patents – resulting 
in “patent thickets” – can inhibit research. Valuable 
biomedical knowledge may be left unused because 
multiple patent owners can exclude one another from 
access to the knowledge. Clinical trials, which test 
the effectiveness and safety of new drugs, should 
be carried out in the developing countries that need 
the drugs. But developing countries tend to lack the 
capacity for clinical trials.
It has been suggested that a prize fund be set 
up to pay those who develop drugs for neglected 
diseases. But it is hard to assess the therapeutic 
benefits of medicines in a timely, independent, and 
valid way. (Most clinical trials of drugs are done 
by the companies that produce them.) Clinical 
trial registries might help by making data more 
available to the public. Drug companies could also 
be required to hand over money for clinical trials to 
a neutral organization. It has also been suggested 
that a voucher system might help reduce barriers 
to research. Companies that work on neglected 
diseases could be given a “voucher” entitling them to 
a priority review for another product. But the voucher 
system is not without problems and should probably 
be abandoned. It is more a model of corporate 
welfare than a system for dealing with the needs 
of developing countries. Ultimately, public-private 
partnerships (PPPs) may be the most promising route 
for increasing R&D for neglected diseases. PPPs 
don’t conduct drug development themselves. But they 
do integrate and coordinate different industry and 
academic partners. That said, PPPs tend to have a 
narrow funding base.
How can you use this research?
This research may prove especially useful to 
policymakers, non-governmental organizations 
(NGOs), researchers, and health care workers who 
want to lower the barriers to research on neglected 
diseases. 
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